StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)

Close on Nov 17, 2026Market cap $96.14MP/E –Yield –

InMed Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

InMed Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$7.86M. For fiscal 2026 it was -$8.64M. The highest annual figure on record is -$6.99M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$8.64M–
FY2025Jun 30, 2025-$8.10M–
FY2024Jun 30, 2024-$6.99M–
FY2023Jun 30, 2023-$7.28M–
FY2022Jun 30, 2022-$15.58M–
FY2021Jun 30, 2021-$9.79M–
FY2020Jun 30, 2020-$7.37M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Sep 30, 2026-$1.14M–
Q4 FY2026CQ2 2026Jun 30, 2026-$2.96M–
Q3 FY2026CQ1 2026Mar 31, 2026-$1.70M–
Q2 FY2026CQ4 2025Dec 31, 2025-$2.05M–
Q1 FY2026CQ3 2025Sep 30, 2025-$1.93M–
Q4 FY2025CQ2 2025Jun 30, 2025-$2.11M–
Q3 FY2025CQ1 2025Mar 31, 2025-$1.66M–
Q2 FY2025CQ4 2024Dec 31, 2024-$2.50M–
Q1 FY2025CQ3 2024Sep 30, 2024-$1.83M–
Q4 FY2024CQ2 2024Jun 30, 2024-$1.03M–
Q3 FY2024CQ1 2024Mar 31, 2024-$1.93M–
Q2 FY2024CQ4 2023Dec 31, 2023-$1.85M–
Q1 FY2024CQ3 2023Sep 30, 2023-$2.17M–
Q4 FY2023CQ2 2023Jun 30, 2023-$657.93K–
Q3 FY2023CQ1 2023Mar 31, 2023-$1.66M–
Q2 FY2023CQ4 2022Dec 31, 2022-$2.71M–
Q1 FY2023CQ3 2022Sep 30, 2022-$2.26M–
Q4 FY2022CQ2 2022Jun 30, 2022-$4.05M–
Q3 FY2022CQ1 2022Mar 31, 2022-$5.35M–
Q2 FY2022CQ4 2021Dec 31, 2021-$3.53M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.65M–
Q4 FY2021CQ2 2021Jun 30, 2021-$2.01M–
Q3 FY2021CQ1 2021Mar 31, 2021-$4.61M–
Q2 FY2021CQ4 2020Dec 31, 2020-$1.80M–
Q1 FY2021CQ3 2020Sep 30, 2020-$1.37M–
Q4 FY2020CQ2 2020Jun 30, 2020-$1.40M–
Q3 FY2020CQ1 2020Mar 31, 2020-$1.52M–
Q2 FY2020CQ4 2019Dec 31, 2019-$2.09M–
Q1 FY2020CQ3 2019Sep 30, 2019-$2.37M–

More InMed Pharmaceuticals figures

See a number that looks wrong?